SEC Form 4 · accession 0001363763-18-000001
RespireRx Pharmaceuticals Inc. · RSPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arnold Lippa
Officer — Exec Chairman, CSO · Director
Period of report
Sep 12, 2018
Accepted (ET)
Sep 14, 2018 · 5:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000849636
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 12, 2018 | P$0 | 47,620 | — | A | 47,620 | D | |
| Common stock | Sep 12, 2018 | G | 47,620 | $0.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Warrants (right to buy)F1 | $1.575 | Sep 12, 2018 | P | 47,620 | A | Sep 12, 2018 | Apr 30, 2023 | Common Stock | 47,620 | 47,620 | D |
| Common stock Warrants (right to buy) | $1.575 | Sep 12, 2018 | G | 47,620 | D | Sep 12, 2018 | Apr 30, 2023 | Common Stock | 47,620 | 0 | D |
Explanation of responses
- F1On April 5, 2018, the Company issued a promissory note to Dr. Lippa in the principal amount of $50,000. On September 12, 2018, the Company redeemed the note, and Dr. Lippa used $50,000 in redemption proceeds to acquire 47,620 units, each unit comprising 47,620 shares of Common Stock and 47,620 Warrants, each Warrant representing the right to purchase an additional share of Common Stock.
- F2Dr. Lippa gifted these securities into a family trust for estate planning purposes. He is not the trustee and does not exercise voting control over shares held in the trust but he is a beneficiary of the trust.